- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Focus Partners Wealth Boosts AbbVie Stake
Institutional investor increases position in pharmaceutical company by 3.2%
Mar. 16, 2026 at 10:05am
Got story updates? Submit your updates here. ›
Focus Partners Wealth, an institutional investor, increased its position in AbbVie Inc. (NYSE: ABBV) by 3.2% during the third quarter, according to a recent 13F filing with the SEC. The firm now owns 649,808 shares of the pharmaceutical company's stock, valued at $150,421,000.
Why it matters
AbbVie is a major pharmaceutical company with a diverse portfolio of drugs, including immunology, oncology, and women's health products. Institutional investors closely monitor the company's performance and ownership changes, as they can signal market sentiment and potential future stock price movements.
The details
Focus Partners Wealth added 20,297 shares to its existing AbbVie position during the third quarter. The firm now owns over 649,000 shares, making it one of the larger institutional holders of the stock. AbbVie's shares have traded in a range of $164.39 to $244.81 over the past 52 weeks.
- Focus Partners Wealth increased its AbbVie stake during the third quarter of 2025.
The players
Focus Partners Wealth
An institutional investment firm that manages a portfolio of stocks, including a significant position in pharmaceutical company AbbVie.
AbbVie Inc.
A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.
The takeaway
The increase in Focus Partners Wealth's AbbVie stake suggests the firm sees continued growth potential in the pharmaceutical company's business and stock performance. As a major institutional investor, Focus Partners Wealth's actions can influence market sentiment and potentially signal broader investor confidence in AbbVie's future prospects.
